Beam Therapeutics BEAM Net investment gains (losses)
Net investment gains (losses) at other companies
Other financials
Where this comes from
Reported directly by Beam Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:EquitySecuritiesFvNiGainLoss.
The official record: Beam Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Beam Therapeutics's net investment gains (losses).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Beam Therapeutics's net investment gains (losses)?
- Beam Therapeutics (BEAM) reported net investment gains (losses) of $16K in Q1 2026.
- How has Beam Therapeutics's net investment gains (losses) changed year-over-year?
- Beam Therapeutics's net investment gains (losses) increased by 100.8% year-over-year, from -$2.08M to $16K.
- What is the long-term trend for Beam Therapeutics's net investment gains (losses)?
- Over 2 years (2022 to 2024), Beam Therapeutics's net investment gains (losses) has grown at a -16.5% compound annual growth rate (CAGR), from $20.2M to -$14.09M.
- What does net investment gains (losses) mean?
- Net realized and unrealized gains and losses on the company's investment portfolio, including equity securities, debt securities, and alternative investments.